Robert Humble
Clinical Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Year:
2026
Year:
2026
Objective ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer. Fluorescence in situ hybridization (FISH) assays can detect the vast majority of ERG gene fusions and help confirm prostatic origin. We reviewed clinical ERG FISH assays performed at our tertiary institution by our in-house consult services between 2016 and 2024 where prostatic adenocarcinoma was in the differential diagnosis. Methods We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered. Results ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n = 4) or undifferentiated (n = 2) disease. Conclusions Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients.
Year:
2026
Objectives The concept of rete hyperplasia with hyaline globules simulating testicular yolk sac tumor was first reported in a mostly retrospective review over 30 years ago. Nonetheless, we continue to encounter examples where this scenario resulted in misdiagnosis. Herein, we sought to investigate the incidence of rete hyperplasia/hyaline globules in germ cell tumors and their associated subtypes and hypothesize an etiology. Methods A consecutive series of 348 germ cell tumor orchiectomies was evaluated for the presence of rete hyperplasia and hyaline globules, with clinicopathologic features recorded. Results The incidence of rete hyperplasia and/or hyaline globules in our cohort was 30%, with 56% of specimens with rete hyperplasia containing concomitant hyaline globules. Hyaline globules were more often identified in specimens with nonfocal rete hyperplasia (78%) vs focal rete hyperplasia (22%). Absence of a yolk sac tumor component was seen in over half (61%) of orchiectomies with concurrent rete hyperplasia/hyaline globules (n = 105), inclusive of tumors with “pure” subtypes (ie, pure seminoma, pure teratoma, or pure embryonal carcinoma). Of these 105 specimens, rete invasion was seen in only 48%; notably, Paneth cell–like metaplasia was identified in efferent ductules/epididymis in 13%. Conclusions Rete hyperplasia and hyaline globules are not uncommon findings in the setting of germ cell tumors (including occurrences in various pure/mixed germ cell tumors) and can show striking overlap with yolk sac tumor. We hypothesize that these histologic pitfalls evolve secondary to testicular obstruction by the tumor mass. Recognition of and distinguishing this morphologic mimicry is fundamental to guide appropriate clinical management.
Year:
2025
Year:
2025
Epithelioid angiomyolipoma (eAML) is an uncommon subtype of angiomyolipoma, a subset of which can demonstrate malignant behavior. While some studies have proposed histopathologic features predictive of aggressive behavior in eAML, there is limited data on the use of immunohistochemistry (IHC) and/or next-generation sequencing (NGS) to identify biomarkers for poor clinical outcome. Moreover, there is limited data on the proposed genetic dichotomy (tuberous sclerosis complex [ TSC ] alteration versus TFE3 rearrangement) of eAML. Clinicopathologic features (including purported histologic features associated with adverse outcome) of 30 eAML were recorded with IHC performed on 1 whole-slide section per tumor for the following markers (interpretations): p16 (positive or negative), p53 (wild type or mutant), TRIM63 ISH (>10% as positive or ≤10% as negative), ATRX (retained or lost), and RB1 (retained or lost). NGS was performed on 23 tumors. The 30 eAML tumors were from 30 patients (23 female, 7 male) of an age range 22 to 77 years (mean=51.9 y). Clinical follow-up was available from 27 patients (mean=36 mo). The features significantly associated with metastatic disease included ≥70% atypical epithelial cells ( P =0.04), ≥2 mitotic figures per 10 high-power fields ( P =0.0013), atypical mitotic figures ( P =0.0003), and necrosis ( P =0.0213). Other features such as local invasion, vascular invasion, tumor size, and immunohistochemical profile (p16, TRIM63, p53, ATRX, and RB1) showed no significant association with the development of metastasis. Interestingly, among the 7 tumors with clinical follow-up showing TFE3 rearrangement, 5 developed metastases (OR=4.50), while 6 of 14 TSC/MTOR mutated tumors with clinical follow-up had metastatic disease (OR=0.222). Notably, TRIM63 ISH showed high sensitivity (100%) for eAML with TFE3 rearrangement but with poor specificity (38%). The genetic dichotomy of eAML comes in the form of TSC/MTOR alterations or TFE3 rearrangement elucidated by NGS, both of which may be associated with poor outcome, and therefore show potential therapeutic implications. As eAML may show overlap with TFE3 -rearranged/ TFEB -altered renal cell carcinoma, shared TRIM63 ISH positivity for these tumor types represents an important potential diagnostic pitfall.
Year:
2025
This case report presents a rare and atypical manifestation of a ureteral Hunner lesion (HL). The patient initially presented with right ureteral stenosis, abnormal urine cytology, intermittent flank pain, gross hematuria, and lower urinary tract symptoms. Diagnostic evaluation involved various imaging studies, endoscopic procedures, and medical interventions. Eventually, the patient underwent right segmental ureterectomy resulting in symptom improvement. Pathology revealed findings consistent with a HL. This case report highlights the challenges in diagnosis, management, and the importance of considering ureteral HL as a potential cause of ureteral symptoms.
Year:
2024
Basal cell carcinoma is an exceedingly rare cause of spinal metastatic disease for which the treatment algorithm is poorly defined. We present a positive patient outcome after treatment of T8 metastatic basal with posterior decompression and fusion followed by later anterior reconstruction, in addition to targeted radiation therapy and pharmacologic therapy. In general, a personalized and comprehensive treatment approach should be used, incorporating surgical, oncologic, and pharmacologic methods as able. Moreover, primary preventive medical and mental health care can help prevent delayed presentation and increased access to timely care.
Year:
2024
Year:
2023
Collaborators (5)
Ulka Vaishampayan
Professor
University of Michigan
Todd Morgan
University of Michigan
Rahul Mannan
Assistant Research Professor & Director Histology Lab
University of Michigan
Simpa Salami
University of Michigan
Sean Williamson
Staff
Cleveland Clinic
Make your next move.
Prepare your application
Review drafts before you send them.